Abstract
19F NMR provided a highly specific tool for identification of efavirenz in human serum and pharmaceutical preparations as well as a suitable analytical technique for their absolute quantification. The method is based on the integration of appropriate signals of efavirenz and potassium fluoride, as an internal standard. The proposed method is simple and reliable, but when it is used without any sample pretreatment, there is a manipulation of large sample volumes and lengthy analysis time. The calibration curve for efavirenz in human serum was linear over the range of 0.8 to 1000 mgL−1, with detection limit of 0.3ï€ mgL−1. The mean error on human serum samples ranged from about -4 to -6%, with relative standard deviations of <8%. The method was also applied successfully for the determination of efavirenz in real pharmaceutical samples,and compared with the results obtained by a reference high-performance liquid chromatography-ultraviolet (HPLC-UV) method. Key words: Efavirenz, 19F NMR analyses, HIV, serum, pharmaceuticals.
Highlights
The calibration curve for efavirenz in human serum was linear over the range of 0.8 to 1000 mg L−1, with detection limit of 0.3 mg L−1
The method was applied successfully for the determination of efavirenz in real pharmaceutical samples, and compared with the results obtained by a reference high-performance liquid chromatography-ultraviolet (HPLC-UV) method
Monitoring of efavirenz levels in plasma could be useful in the clinical management of HIV disease, especially in HIV-TB coinfected patients, who are being treated with efavirenz and rifampicin concomitantly (Novakova and Vlckova, 2009)
Summary
Efavirenz is the preferential choice to treat HIV-tuberculosis (TB) coinfected patients (Katijah, 2010). Management of both of these diseases is complicated due to pharmacological drug-drug interactions between efavirenz and rifampicin, which is a first-line anti-TB drug and a potent inducer of the cytochrome P-450 system (Ramachandran et al, 2006). Treatment failure and central nervous system side effects have been found to be associated with low and high efavirenz plasma levels. Monitoring of efavirenz levels in plasma could be useful in the clinical management of HIV disease, especially in HIV-TB coinfected patients, who are being treated with efavirenz and rifampicin concomitantly (Novakova and Vlckova, 2009)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
